Silo Pharma (NASDAQ: SILO) Secures European Patent for Innovative PTSD Prevention Therapy

April 6, 2026

Key Developments Silo Pharma (NASDAQ: SILO) has been granted a key patent allowance by the European Patent Office (EPO) concerning its novel therapy designed to prevent post-traumatic stress disorder (PTSD). The patent specifically covers the preventive application of treatments targeting the 5-HT4 receptor pathway, a significant advancement in the company’s intellectual property (IP) portfolio. This development marks a crucial milestone, expanding Silo Pharma’s IP assets related to its licensed PTSD…

Read More >>